BridgeMD
New treatment option for 22q11.2 Deletion Syndrome
Official title Understanding of Psychotic Disorders in Children With 22q11.2DS
ClinicalTrials.gov ID: NCT04639388
What this study is testing
- What it's testing
- The study PremiCeS22 will investigate the prodromal signals at the onset of psychotic disorders of children with 22q11.2 deletion syndrome
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 4 to 13. Healthy volunteers may be eligible.
You may be able to join if
- Diagnosis of 22q11.2 deletion syndrome or no developmental disease
- Aged from 4 to 13 years old
- French language
You likely can't join if
- Diagnosis of intellectual deficiency according to DSM 5 criteria
- Drug prescribed for somatic condition that could influence cerebral functioning
The study team makes the final eligibility decision.
Where it's taking place
- Lyon, Auvergne-Rhône-Alpes, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 4 years to 13 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Lyon, Auvergne-Rhône-Alpes, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.